CalciMedica, Inc.
CALCNASDAQHealthcareBiotechnology
Previous close
$0.5728
−$0.0104 · -1.78%
CALC company overview
Regular session · ET · Market data may be delayed.
GoAI snapshot
AI-powered factor overview
GoAI score
Sell
Trim exposure — unfavorable risk-reward
Valuation
27
Expensive
Momentum
36
Weakening
Sentiment
45
Mixed
Risk resilience
31
High Risk
Full GoAI research
Thesis, catalysts, evidence, and risk analysis.
AI-generated, informational only, and not investment advice.
Company profile
Company websiteCalciMedica, Inc., a clinical-stage biotechnology company headquartered in La Jolla, California, is focused on creating treatments for life-threatening inflammatory diseases that currently lack adequate therapies. The company's proprietary approach involves blocking calcium release-activated (CRAC) channels, a mechanism designed to modulate the immune system and protect against cellular and tissue damage in these severe conditions. Their primary experimental drug, Auxora, is an intravenously administered, proprietary CRAC channel inhibitor being developed for the treatment of acute pancreatitis, including its asparaginase-associated form, and acute kidney injury.
- Industry
- Biotechnology
- Sector
- Healthcare
- Headquarters
- US
- CEO
- A. Rachel Leheny
- Listed since
- Jun 14, 2023
- Employees
- 16
Market position
Day range
Current $0.5728
52-week range
Current $0.5728
- Open
- $0.593
- Previous close
- $0.5832
- Volume
- 271.59K
- 0.22× average
- Average volume
- 1.23M
- Average daily volume
- Market cap
- 9.02M USD
- Beta
- 1.12
- Market reference 1
- 50-day average
- $0.7778
- -26.36% below average
- 200-day average
- $1.8516
- -69.07% below average
Financials
Financial snapshot
Latest / TTMValuation & yield
- Enterprise value
- 98.92B USD
- P/E (TTM)
- -0.42×
- P/B (TTM)
- 1.78×
- P/S (TTM)
- 0×
- EV / EBITDA
- -3,521.14×
- Earnings yield
- -0.03%
- Free cash flow yield
- -0.02%
- Dividend yield
- 0.00%
Profitability & efficiency
- Gross margin
- 0.00%
- Operating margin
- 0.00%
- Net margin
- 0.00%
- Return on equity
- 445.14%
- Return on assets
- -217.51%
- Return on invested capital
- -209.07%
Financial health
- Debt / equity
- 0×
- Current ratio
- 3.58×
- Altman Z-score
- -15.79
- Piotroski F-score
- 3 of 9
Financial statements
Income trends
Operating income
Net income
| Metric (USD) | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|
| Cost of goods sold | 46K USD | — | — | — | 519K USD |
| Gross profit | −46K USD | — | — | — | −519K USD |
| Research and development | 15.23M USD | 14.48M USD | 15.86M USD | 8.35M USD | 18.9M USD |
| Selling, general, and administrative | 7.89M USD | 9.73M USD | 22.22M USD | 5.84M USD | 17.04M USD |
| Operating expenses | 23.12M USD | 24.2M USD | 38.08M USD | 14.19M USD | 35.43M USD |
| Interest income | 713K USD | — | — | — | 126K USD |
| Interest expense | 1.42M USD | — | 110K USD | 132K USD | 126K USD |
| Depreciation and amortization | 46K USD | 58K USD | 58K USD | 52K USD | 519K USD |
| Operating income | −23.12M USD | −24.2M USD | −38.08M USD | −14.19M USD | −35.95M USD |
| Net income | −29.56M USD | −13.7M USD | −34.36M USD | −7.82M USD | −35.82M USD |
Company facts updated Aug 24, 2026.
Earnings
- EPS beat rate
- 55%
- 6 beats, 4 misses, 1 met estimate
- Average EPS surprise
- +3.73%
- 11 comparable reports
- Latest EPS result
- -0.45
- Estimate -0.29 · Miss by 57.89%
EPS: actual versus estimate
Recent quarterly results
Analyst ratings
Third-party consensus; not a GoAI recommendation.
Analyst price target
Average target
$266
46338.55% upsideRating distribution
3 ratingsLimited analyst sample: 3 ratings. Interpret the distribution with caution.
Recent analyst actions
CALC news
Corporate actions
Corporate action history
| Action | Effective date | Details | Record date | Payment date |
|---|---|---|---|---|
Stock split | Mar 20, 2023 | 1:14 | — | — |
Effective Mar 20, 2023
1:14
CALC peers
ETFs holding CALC
Funds reporting this stock among their holdings, ordered by reported position size.
Continue in GoAI
Research CALCresearch.disclaimer